Diaceutics (DXRX) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Jun 2020 02:55 PM
RNS
Result of General Meeting
19 Jun 2020 07:00 AM
RNS
Holding(s) in Company
11 Jun 2020 02:00 PM
RNS
Exercise of warrant
11 Jun 2020 07:00 AM
RNS
Placing of £20.5 million
19 May 2020 02:29 PM
RNS
Result of AGM
19 May 2020 07:00 AM
RNS
AGM Statement
18 May 2020 07:00 AM
RNS
Diagnostic network for precision medicine update
05 May 2020 11:22 AM
RNS
Director's Shareholding - PCA Dealing
29 Apr 2020 07:00 AM
RNS
Cancer testing & diagnosis suffers sharp downturn
23 Apr 2020 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
06 Apr 2020 07:00 AM
RNS
Issue of Share Options
19 Mar 2020 07:00 AM
RNS
Belfast investor presentation
17 Mar 2020 09:05 AM
RNS
Second Price Monitoring Extn
17 Mar 2020 09:00 AM
RNS
Price Monitoring Extension
16 Mar 2020 11:05 AM
RNS
Second Price Monitoring Extn
16 Mar 2020 11:00 AM
RNS
Price Monitoring Extension
16 Mar 2020 07:00 AM
RNS
Final Results
12 Mar 2020 02:24 PM
RNS
Private investor briefing
27 Feb 2020 07:00 AM
RNS
Notice of Results
17 Feb 2020 07:00 AM
RNS
Belfast investor presentation
06 Feb 2020 07:00 AM
RNS
Growth & Innovation Forum 2020
17 Jan 2020 02:53 PM
RNS
Holding(s) in Company
13 Jan 2020 09:05 AM
RNS
Second Price Monitoring Extn
13 Jan 2020 09:00 AM
RNS
Price Monitoring Extension
13 Jan 2020 07:00 AM
RNS
Year-End Trading Update
25 Nov 2019 07:00 AM
RNS
Presentation at AICon 2019
24 Oct 2019 07:00 AM
RNS
Presentation at Big Data Belfast
21 Oct 2019 07:00 AM
RNS
Pharma Precision Medicine Readiness Report
10 Oct 2019 07:00 AM
RNS
Workshop presentation at EORTC
30 Sep 2019 08:01 AM
RNS
Poster presentation at ESMO
23 Sep 2019 07:00 AM
RNS
Dublin investor presentation
09 Sep 2019 07:00 AM
RNS
Half-year Report
08 Aug 2019 07:00 AM
RNS
Appointment of Head of Global Data
08 Aug 2019 07:00 AM
RNS
Notice of Results
08 Jul 2019 07:00 AM
RNS
Trading update
17 Jun 2019 07:00 AM
RNS
Investment in data lake
28 May 2019 07:00 AM
RNS
Investor presentation
25 Mar 2019 04:29 PM
RNS
Holding(s) in Company
25 Mar 2019 07:00 AM
RNS
Holding(s) in Company
21 Mar 2019 02:05 PM
RNS
Second Price Monitoring Extn
21 Mar 2019 02:00 PM
RNS
Price Monitoring Extension
21 Mar 2019 07:00 AM
RNS
Admission to AIM & First Day of Dealings

Diaceutics PLC, a global leader in the field of precision medicine, holds a significant position on the London Stock Exchange (LSE). As part of the dynamic financial ecosystem facilitated by the London Stock Exchange Group (LSEG), Diaceutics PLC contributes to the global financial landscape.

The Diaceutics share price and DXRX share price are key indicators of the company's market performance. These metrics are closely monitored by investors to assess the company's financial health and make informed investment decisions.

Founded in 2005, Diaceutics PLC is headquartered in Belfast, United Kingdom. The company has been a pioneer in the field of diagnostic testing, collating large amounts of laboratory, patient, claims, and payor data which it uses to deliver diagnostic testing strategies to its clients. Over the years, Diaceutics PLC has amassed a set of data from over 52,515 laboratories, showing disease volumes and 481 million de-identified patient records globally in 53 countries. This data collection has allowed the company to accumulate a proprietary database of laboratory capabilities across the industry.

Diaceutics PLC provides services to 39 global pharmaceutical companies and is focused on optimising its clients’ strategies for the development and launch of precision medicines. Precision medicines are a class of drug tailored to individual patient groups dependent on molecular or genetic factors of the individual. Today, they are used for treatment in oncology as well as other disease areas such as multiple sclerosis and rheumatoid arthritis.

Being listed on the LSE, Diaceutics PLC is part of the vibrant financial ecosystem facilitated by the London Stock Exchange Group (LSEG). LSEG, a leading global financial markets infrastructure and data provider, plays a crucial role in supporting the financial stability and growth of communities and economies globally.

In conclusion, Diaceutics PLC, with its strategic focus on precision medicine and its status as a company listed on the LSE, represents a noteworthy entity in the financial markets landscape facilitated by LSEG. Its share price, referred to as both Diaceutics share price and DXRX share price, are key considerations for investors, reflecting the company's market performance. As part of the vibrant LSEG ecosystem, Diaceutics PLC contributes to the broader financial markets infrastructure, underscoring its significance in the global financial community.

UK 100